Publications by Professor Herbie Newell - ePrints

Browsing publications by Professor Herbie Newell.

Newcastle Authors	Title	Year
Christopher Matheson Christopher Coxon Dr Benoit Carbain Dr Ian Hardcastle Dr Suzannah Harnor et al.	2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase	2020
Professor Herbie Newell	A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA	2019
Liz Matheson Huw Thomas Marian Case Dr Helen Blair Rosanna Jackson et al.	Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM	2019
Stephanie Myers Duncan Miller Dr Lauren Molyneux Dr Mercedeh Arasta Dr Ruth Bawn et al.	Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4	2019
Dr Lindi Chen Philip Berry Dr Jennifer Bonner Calum Kirk Dr Katrina Wood et al.	Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma	2019
Dr Catherine Willoughby Huw Thomas Dr Elaine Willmore Suzanne Kyle Dr Anita Wittner et al.	Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy	2019
Honorine Lebraud Dr Richard Noble Nicole Phillips Dr Yan Zhao Professor Herbie Newell et al.	A highly potent clickable probe for cellular imaging of MDM2 and assessing dynamic responses to MDM2-p53 inhibition	2018
Christopher Coxon Dr Suzannah Harnor Dr Mathew Martin Dr Benoit Carbain Emeritus Professor Bernard Golding et al.	Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines	2017
Professor Herbie Newell	Discovery & pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor	2017
Dr Lindi Chen Philip Berry Dr Jennifer Bonner Dr Katrina Wood Professor Gareth Veal et al.	In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma	2017
Carlo Bawn Dr Martin Galler Huw Thomas Suzanne Kyle Professor Nicola Curtin et al.	PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS	2017
Dr Britta Vormoor Yvonne Schlosser Dr Helen Blair Abhishek Sharma Sarah Wilkinson et al.	Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2	2017
Dr Christopher Wong Dr Ian Hardcastle Christopher Matheson Professor Herbie Newell Dr Mangaleswaran Sivaprakasam et al.	Structure-guided design of purine-based probes for selective Nek2 inhibition	2017
Dr Catherine Drummond Arman Esfandiari Dr Xiaohong Lu Dr Claire Hutton Dr Jennifer Jackson et al.	TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation	2016
Dr Gary Beale Dr Emma Haagensen Huw Thomas Lan Wang Charlotte Revill et al.	Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer	2016
Tristan Reuillon Dr Sari Alhasan Dr Gary Beale Annalisa Bertoli Alfie Brennan et al.	Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases	2016
Dr Emma Haagensen Huw Thomas Dr Ross Maxwell Professor Herbie Newell	Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037	2016
Dr Rachel Pearson Professor Peter Thelwall Jim Snell Dr Piotr Pieniazek Professor Rakesh Heer et al.	Evaluation of early responses to neoadjuvant chemotherapy in muscle-invasive bladder cancer using a dynamic contrast-enhanced MRI and diffusion-weighted MRI: MARBLE study	2016
Stephanie Myers Dr Ruth Bawn Betty Cottyn Dr Lauren Molyneux Dr Celine Cano et al.	High-throughput screening and hit validation of extracellular-related kinase 5 (ERK5) inhibitors	2016
Dr Emma Haagensen Huw Thomas Dr Ross Maxwell Professor Herbie Newell	Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent	2016
Dr Sari Alhasan Dr Beate Haugk Laura Ogle Dr Gary Beale Anna Long et al.	Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma	2016
Lan Wang Professor Herbie Newell Professor Steve Wedge	Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation	2016
Liam Cornell Dr Joanne Martin Laura Ogle Dr Catherine Willoughby Dr Despina Televantou et al.	DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival	2015
Elisa Meschini Dr Regina Mora Vidal Dr Mathew Martin Dr Will Stanley Tristan Reuillon et al.	Identification and characterization of an irreversible inhibitor of CDK2	2015
Dr Britta Vormoor Yvonne Schlosser Dr Helen Blair Sarah Wilkinson Professor Herbie Newell et al.	Inhibition of DNA-Repair Enzymes (DNA-Pk and Parp) to Sensitize Ewing Sarcoma to Chemo-And Radiotherapy	2015
Dr Lindi Chen Professor Herbie Newell Professor John Lunec Professor Deborah Tweddle	Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma	2015
Duncan Miller Dr Benoit Carbain Dr Gary Beale Dr Sari Alhasan Professor Helen Reeves et al.	Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases	2015
Dr Andrey Zaytsev Dr Barry Dodd Emeritus Professor Bernard Golding Professor Roger Griffin Dr Xiaohong Lu et al.	Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach	2015
Laura Evans Dr Lindi Chen Dr Elaine Willmore Professor Herbie Newell Professor Deborah Tweddle et al.	SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma	2015
Andrew Shouksmith Laura Evans Professor Deborah Tweddle Duncan Miller Dr Elaine Willmore et al.	Synthesis and Activity of Putative Small-Molecule Inhibitors of the F-Box Protein SKP2	2015
Dr Benoit Carbain Dr Allyson Campbell Dr Celine Cano Professor Jane Endicott Emeritus Professor Bernard Golding et al.	8-Substituted O-6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode	2014
Alex Liu Dr Catherine Drummond Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al.	An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones	2014
Honorine Lebraud Emeritus Professor Bernard Golding Elisa Meschini Dr Celine Cano Lan Wang et al.	Anticancer agents targeted against cyclin-dependent kinase 2 (CDK2): Structure-based design of irreversible and reversible inhibitors	2014
Andrew Shouksmith Laura Evans Professor Roger Griffin Emeritus Professor Bernard Golding Professor Herbie Newell et al.	Design and synthesis of putative small-molecule inhibitors targeting the SCFSKP2 E3 ligase complex	2014
Dr Ruth Bawn Tristan Reuillon Emeritus Professor Bernard Golding Professor Roger Griffin Dr Ian Hardcastle et al.	Development of extracellular signal-regulated kinase 5 (ERK5) inhibitors for anti-cancer therapy	2014
Professor Herbie Newell	Discovery of JNJ-42756493, a potent fibroblast growth factor receptor (FGFR) inhibitor using a fragment based approach	2014
Emily Mould Professor Herbie Newell Dr Elaine Willmore	DNA-PK is activated by microtubule-targeting agents; mechanistic studies using isogenic wild-type and DNA-PK knockout cells	2014
Dr Britta Vormoor Dr Yan Zhao Professor Herbie Newell	Evaluating the activity of the p53-MDM2 inhibitor NDD0005 in Ewing sarcoma	2014
Dr Mathew Martin Elisa Meschini Lan Wang Dr Regina Mora Vidal Tristan Reuillon et al.	Identification and characterization of an irreversible inhibitor of CDK2	2014
Emily Mould Philip Berry Dr David Jamieson Dr Chris Hill Dr Celine Cano et al.	Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity	2014
Lynsey Fazal Professor Herbie Newell	JNJ-42756493 is an inhibitor of FGFR-1, 2, 3 and 4 with nanomolar affinity for targeted therapy	2014
Professor Herbie Newell	Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine	2014
Dr Susan Tudhope Dr Yan Zhao Dr Anita Wittner Annalisa Bertoli Santosh Adhikari et al.	Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels	2014
Dr Lindi Chen Dr Yan Zhao Dr Gail Halliday Philip Berry Professor Herbie Newell et al.	Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma	2014
Dr Suzannah Harnor Dr Tommy Rennison Dr Martin Galler Dr Celine Cano Professor Roger Griffin et al.	Synthesis of 3 '-deoxy-3'-fluorothymidine (FLT) 5 '-O-glucuronide: a reference standard for imaging studies with [¹⁸F]FLT	2014
Emily Mould Stephanie Burnell Philip Berry Professor Herbie Newell Dr Elaine Willmore et al.	The novel and contrasting roles of ATM and DNA-PK in the response of cells to microtubule-targeting anticancer agents	2014
Annalisa Bertoli Santosh Adhikari Dr Suzannah Harnor Dr Yan Zhao Professor John Lunec et al.	Validation studies with small-molecule modulators of the MDM2/MDMX-p53 binding interaction	2014
Dr Celine Cano Dr Kappusamy Saravanan Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK PI3-K Inhibitory Activity	2013
Dr Tommy Rennison Sonsoles Rodriguez-Aristegui Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)	2013
Dr Tim Blackburn Christopher Coxon Dr Xiaohong Lu Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions	2013
Michael Batey Dr Yan Zhao Suzanne Kyle Professor Herbie Newell Professor Nicola Curtin et al.	Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer	2013
Sarah Cully Dr Celine Cano Emeritus Professor Bernard Golding Professor Roger Griffin Professor John Lunec et al.	Regiospecific synthesis of isoindolinones as MDM2 inhibitors	2013
Emily Mould Philip Berry Dr David Jamieson Dr Chris Hill Niu Tan et al.	The DNA-PK inhibitor, NU7441, sensitises cancer cells to microtubule-targeting agents and modulates vincristine efflux in multidrug resistant cells	2013
Dr Emma Haagensen Huw Thomas Ian Wilson Dr Suzannah Harnor Sara Payne et al.	The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [¹⁸F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice	2013
Dr Kelly Coffey Dr Tim Blackburn Susan Cook Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer	2012
Dr Joanne Martin Michael Batey Dr Yan Zhao Dr Celine Cano Dr Michele Tavecchio et al.	Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K	2012
Dr Michele Tavecchio Dr Joanne Martin Dr Celine Cano Professor Herbie Newell Professor Nicola Curtin et al.	Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination	2012
Dr Sari Alhasan Dr Gary Beale Professor Herbie Newell Professor Helen Reeves	Suppression of SULF2, an extracellular endosulfatase up-regulated in hepatocellular cancers, modulates WNT signalling and inhibits cell growth	2012
Dr Emma Haagensen Suzanne Kyle Dr Gary Beale Dr Ross Maxwell Professor Herbie Newell et al.	The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition	2012
Michael Batey Dr Yan Zhao Dr Helen Maitland Professor Hing Leung Dr Andrew Hall et al.	Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma	2011
Huw Thomas Professor Herbie Newell Professor Nicola Curtin	Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition	2011
Dr Ian Hardcastle Alex Liu Dr Eric Valeur Anna Watson Shafiq Ahmed et al.	Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency	2011
Dr Karim Bennaceur Dr Catherine Drummond Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al.	MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones	2011
Dr Kappusamy Saravanan Hannah Barlow Marion Barton Professor Hilary Calvert Emeritus Professor Bernard Golding et al.	Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α₁-Acid Glycoprotein	2011
Michael Batey Professor Julie Irving Professor Herbie Newell	Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models	2011
Huw Thomas Dr Celine Roche Dr Johanne Bentley Dr Ian Hardcastle Emeritus Professor Bernard Golding et al.	Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301	2011
Dr Simon Pridgeon Professor Rakesh Heer Gordon Taylor Professor Herbie Newell Kieran O'Toole et al.	Thiothymidine combined with UVA as a potential novel therapy for bladder cancer	2011
Elisa Meschini Professor Jane Endicott Emeritus Professor Bernard Golding Dr Ian Hardcastle Professor Herbie Newell et al.	Design and synthesis of dual CDK2 and CDK7 inhibitors	2010
Dr Kate Smith Dr Tommy Rennison Sonsoles Rodriguez-Aristegui Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)	2010
Dr Celine Cano Dr Olivier Barbeau Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype	2010
Dr Nicola Johnson Dr Johanne Bentley Lan Wang Professor Herbie Newell Professor Craig Robson et al.	Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells	2010
Dr Benoit Carbain Dr Celine Roche Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Celine Cano et al.	Structure-based design of C8-substituted O6-alkylguanine CDK1 and 2 inhibitors	2010
Dr Francesco Marchetti Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Synthesis and biological evaluation of 5-substituted O⁴-alkylpyrimidines as CDK2 inhibitors	2010
Liam Cornell Dr Joanne Martin Febrina Budhisetiawan Professor Herbie Newell Professor Derek Manas et al.	Synthetic lethality in liver cancer cell lines treated with inhibitors of DNA double strand break repair	2010
Huw Thomas Dr Kappusamy Saravanan Lan Wang Mei Lin Dr Julian Scott Northen et al.	Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity	2009
Dr Celine Roche Professor Steve Wedge Professor Herbie Newell Dr Michael Tilby	The kinase inhibitor O⁶-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2	2009
Professor Herbie Newell Huw Thomas Lan Wang Dr Celine Roche Dr Ian Hardcastle et al.	[abstract] Preclinical in vitro and in vivo evaluation of the cyclin dependent kinase 2 inhibitor NU6102 and a water pro-drug NU6301	2008
Michael Batey Professor Herbie Newell Professor Nicola Curtin	Chemosensitisation of cancer cells by KU-0060648, a potent and selective inhibitor of DNA-PK [abstract]	2008
Michael Batey Dr Amy Peasland Professor Julie Irving Professor Herbie Newell	Development of inhibitors of the fibroblast growth factor receptor (FGFR) kinase using a fragment based approach	2008
Dr Kappusamy Saravanan Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Karen Haggerty et al.	Identification of potent water-soluble DNA-dependent protein kinase (DNA-PK) inhibitors using a small-molecule library approach [abstract]	2008
Michael Batey Dr Helen Maitland Professor Hing Leung Dr Andrew Hall Professor Graham Jackson et al.	In vitro activity of the multi targeted receptor tyrosine kinase inhibitor sunitinib against multiple myeloma cell lines is not predictive of in vivo xenograft response	2008
Dr Xiaomei Lu Alex Liu Dr Ian Hardcastle Professor Roger Griffin Emeritus Professor Bernard Golding et al.	MDM2 and MDMX status as a determinant of in vitro cellular sensitivity to MDM2 antagonists in human tumour cell lines	2008
Emeritus Professor Bernard Golding Professor Roger Griffin Dr Claire Hutton Professor John Lunec Professor Herbie Newell et al.	MEDI 147-Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction	2008
Professor Ruth Plummer Dr Christopher Jones Professor Nicola Curtin Professor Alan Boddy Professor Herbie Newell et al.	Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors	2008
Michael Batey Dr Laurent Rigoreau Professor Roger Griffin Professor Herbie Newell Professor Nicola Curtin et al.	Potent in vitro and in vivo radiosensitisation by the selective DNA-dependent protein kinase inhibitor KU-0060648 [abstract]	2008
Professor Herbie Newell	Professor Lloyd R. Kelland: man of science	2008
Lan Wang Professor Nicola Curtin Professor Herbie Newell	Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked	2008
Huw Thomas Gordon Taylor Professor Herbie Newell Professor Alan Boddy	An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed	2007
Professor Alan Boddy Julieann Sludden Melanie Griffin Professor Herbie Newell Professor Stephen O'Brien et al.	Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia	2007
Huw Thomas Dr Christopher Calabrese Michael Batey Suzanne Kyle Professor Herbie Newell et al.	Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial	2007
Jonathan Hollick Dr Laurent Rigoreau Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase	2007
Dr Francesco Marchetti Kerry Louise Sayle Dr Johanne Bentley Professor William Clegg Professor Nicola Curtin et al.	Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6- aminopyrimidine inhibitors of cyclin-dependent kinase 2	2007
Huw Thomas Dr Christopher Calabrese Professor Herbie Newell Lan Wang Professor Nicola Curtin et al.	Identification of a PARP inhibitor for clinical trial: Preclinical studies	2006
Dr Yan Zhao Huw Thomas Michael Batey Dr Ian Cowell Professor Roger Griffin et al.	Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441	2006
Professor Roger Griffin Andrew Henderson Professor Nicola Curtin Professor Jane Endicott Dr Ian Hardcastle et al.	Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination	2006
Dr Ian Hardcastle Dr Shafiq Ahmed Helen Atkins Gillian Farnie Emeritus Professor Bernard Golding et al.	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold	2006
Professor Herbie Newell Professor Roger Griffin Richard Davison Lan Wang Professor Nicola Curtin et al.	Effect of cell cycle inhibition on cisplatin-induced cytotoxicity	2005
Professor Ruth Plummer Professor Alan Boddy Professor Nicola Curtin Professor Herbie Newell Lynsey Robson et al.	Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide	2005
Professor Herbie Newell	Has chemotherapy reached its limits in pediatric cancers? Commentary	2005
Professor Herbie Newell	How to develop a successful cancer drug - molecules to medicines or targets to treatments?	2005
Dr Ian Hardcastle Dr Shafiq Ahmed Professor Alan Calvert Professor Nicola Curtin Gillian Farnie et al.	Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction	2005
Professor Roger Griffin Dr YuZhu Cheng Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	Potent CDK2 inhibitors generated using a variant of the cope elimination	2005
Dr Allyson Campbell Dr YuZhu Cheng Lan Wang Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: A possible role for survivin down-regulation	2005
Andrew Henderson Dr YuZhu Cheng Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Searching for potent CDK2 inhibitors using a variant of the Cope elimination	2005
Professor Ruth Plummer Dr Christopher Jones Professor Alan Boddy Professor Alan Calvert Professor Herbie Newell et al.	Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O⁶-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1	2005
Dr Christopher Calabrese Michael Batey Professor Alan Calvert Professor barbara Durkacz Suzanne Kyle et al.	Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361	2004
Dr Christopher Calabrese Professor Nicola Curtin Suzanne Kyle Huw Thomas Lan Wang et al.	Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase	2004
Dr Xiaohong Lu Professor Herbie Newell Professor Andrew Pearson Professor John Lunec	Identification of MYCN transcriptional activity inhibitors yields compounds which preferentially inhibit the growth of neuroblastoma cells	2004
Dr Ian Hardcastle Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin Professor Jane Endicott et al.	N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2	2004
Professor Nicola Curtin Lan Wang Suzanne Kyle Dr Christine Arris Professor barbara Durkacz et al.	Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells	2004
Professor Herbie Newell	Preclinical models in cancer drug discovery and development	2004
Professor Nicola Curtin Hannah Barlow Professor Alan Calvert Richard Davison Emeritus Professor Bernard Golding et al.	Resistance-modifying agents. 11. Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to α₁-acid glycoprotein	2004
Professor Herbie Newell	The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies	2004
Professor Alan Boddy Gordon Taylor Dr Andrew Hughes Professor Alan Calvert Professor Herbie Newell et al.	2-[¹¹C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337	2003
Dr Veronique Mesguiche Rachel Parsons Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin et al.	4-Alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kinases 1 and 2	2003
Dr Christopher Calabrese Michael Batey Huw Thomas Professor barbara Durkacz Lan Wang et al.	Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies	2003
Huw Thomas Gordon Taylor Professor Herbie Newell Professor Alan Boddy	Potentiation of raltitrexed (RTX) in vitro by thymidine phosphorylase (TP) and TP distribution in vivo	2003
Professor Herbie Newell	Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK	2003
Kerry Louise Sayle Dr Johanne Bentley Professor Alan Calvert Dr YuZhu Cheng Professor Nicola Curtin et al.	Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2	2003
Professor Herbie Newell	The drug development process: from target discovery to the clinic	2003
Professor Nicola Curtin Professor Herbie Newell Professor Alan Calvert Professor Roger Griffin Emeritus Professor Bernard Golding et al.	Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors	2003
Professor Herbie Newell	"Be brilliant!" - a tribute to Tom Connors	2002
Professor Herbie Newell	A study of amsalog (c1-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation	2002
Timothy Cressey Dr Michael Tilby Professor Herbie Newell	Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines	2002
Noel Monks Professor Nicola Curtin Dr Christine Arris Professor Herbie Newell	DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767	2002
Professor Herbie Newell	Getting the right dose in cancer chemotherapy - time to stop using surface area?	2002
Dr Christopher Calabrese Professor Nicola Curtin Suzanne Kyle Huw Thomas Lan Wang et al.	Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure	2002
Michael Batey Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al.	Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)	2002
Michael Batey Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al.	Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)	2002
Dr Ashleigh Gibson Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin Professor Jane Endicott et al.	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O6-substituted guanine derivatives	2002
Huw Thomas Mike Cole Suzanne Elliott Professor Herbie Newell Professor Alan Calvert et al.	Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide	2002
Dr Johanne Bentley Dr Christine Arris Professor Nicola Curtin Professor Jane Endicott Dr Ashleigh Gibson et al.	Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor	2002
Huw Thomas Gordon Taylor Professor Herbie Newell Professor Alan Boddy	The in vivo distribution of a CEA directed antibody conjugated to thymidine phosphorylase	2002
Professor Herbie Newell	The EORTC Laboratory Research Division	2002
Dr Xiaomei Lu Julie Errington Professor Nicola Curtin Professor John Lunec Professor Herbie Newell et al.	The impact of p53 status on cellular sensitivity to antifolate drugs	2001
Professor Herbie Newell Professor Alan Boddy Geoffrey Taylor Andrew Johnston Professor Andrew Pearson et al.	A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation	2001
Professor Nicola Curtin Dr Stephen Barton Michael Batey Dr Christopher Calabrese Professor Alan Calvert et al.	Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.	2001
Professor Herbie Newell Professor Alan Calvert Professor Nicola Curtin	Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro	2001
Professor Herbie Newell	European Organization for Research and Treatment of Cancer (EORTC) Laboratory Research Division workshop on the role of in vivo pre-clinical models in the development of contemporary cancer therapeutics, Verona, Italy, 3 February 2001	2001
Professor Herbie Newell	Flasks, fibres and flanks - Pre-clinical tumour models for predicting clinical antitumour activity	2001
Gordon Taylor Huw Thomas Professor Herbie Newell Professor Nicola Curtin	Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole	2001
Peter Smith Huw Thomas Hannah Barlow Professor Roger Griffin Emeritus Professor Bernard Golding et al.	In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity	2001
Noel Monks Professor Nicola Curtin Professor Herbie Newell	Induction of apoptosis by the ADEPT agent ZD2767: Comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue	2001
Professor Gareth Veal Dr Cinera Dias Annie Parry Julie Errington Dr Juliet Hale et al.	Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy	2001
Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin Dr Ian Hardcastle et al.	Inhibiting the MDM2-p53 interaction using low molecular weight compounds	2001
Dr Stephany Veuger Professor barbara Durkacz Emeritus Professor Bernard Golding Professor Roger Griffin Professor Herbie Newell et al.	Radiosensitization by novel inhibitors of PARP, PI, and DNA-PK, NU7026, in vitro	2001
Professor Herbie Newell	Review of clinical trials with cell cycle based strategies	2001
Professor Martin Noble Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson et al.	Structural and thermodynamic validation of inactive cdk2 as a template for structure-based drug design	2001
Professor Martin Noble Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Structure based design of a potent inhibitor of cdk2	2001
Lan Wang Professor Nicola Curtin Professor Herbie Newell	Tumor radiosensitization using TBI-361, an inhibitor of poly (ADP-ribose) polymerase (PARP)	2001
Peter Smith Huw Thomas Hannah Barlow Professor Roger Griffin Emeritus Professor Bernard Golding et al.	In vitro activity and in vivo pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU3121	2000
Dr Xiaohong Lu Julie Errington Professor Nicola Curtin Professor Alan Boddy Professor Herbie Newell et al.	Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines	2000
Noel Monks Professor Nicola Curtin Professor Herbie Newell	Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)	2000
Professor Nicola Curtin Professor Alan Calvert Professor barbara Durkacz Professor Roger Griffin Emeritus Professor Bernard Golding et al.	Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines.	2000
Dr Andrew Hughes Melanie Griffin Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al.	Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq(TM)) and paclitaxel	2000
Dr Christopher Calabrese Professor Nicola Curtin Michael Batey Huw Thomas Suzanne Kyle et al.	Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase	2000
Professor Roger Griffin Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson et al.	Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors	2000
Gordon Taylor Professor Herbie Newell	Development of a whole cell assay to measure methotrexate-induced inhibition of thymidylate synthase and de novo purine synthesis in leukaemia cells	2000
Peter Smith Professor Herbie Newell Professor Nicola Curtin	Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport	2000
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson Emeritus Professor Bernard Golding et al.	Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles	2000
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott Emeritus Professor Bernard Golding et al.	Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles	2000
Professor Gareth Veal Dr Cinera Dias Professor Alan Boddy Annie Parry Dr Juliet Hale et al.	In vitro/in vivo correlations of cisplatin-DNA adduct levels in leucocytes of children	2000
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin et al.	O6-substituted guanines and 4-substituted pyrimidines: a novel class of antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.	2000
Lan Wang Suzanne Kyle Alex White Professor Alan Calvert Professor Nicola Curtin et al.	Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines	2000
Huw Thomas Professor Alan Boddy Professor Andrew Pearson Professor Herbie Newell	Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial	2000
Professor Roger Griffin Dr Christine Arris Dr Christine Bleasdale Professor Alan Calvert Professor Nicola Curtin et al.	Resistance-modifying agents. 8. Inhibition of O⁶-alkylguanine-DNA alkyltransferase by O⁶-alkenyl-, O⁶-cycloalkenyl-, and O⁶-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O⁶-(1-cyclopentenylmethyl) guanine	2000
Alex White Professor Alan Calvert Professor Nicola Curtin Professor Roger Griffin Professor Herbie Newell et al.	Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase	2000
Hannah Barlow Professor Nicola Curtin Professor Alan Calvert Emeritus Professor Bernard Golding Professor Herbie Newell et al.	Resistance-modifying agents. Part 7: 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of α1-acid glycoprotein (AGP)	2000
Dr Johanne Bentley Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott et al.	Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors	2000
Professor Roger Griffin Hannah Barlow Professor Nicola Curtin Professor Alan Calvert Emeritus Professor Bernard Golding et al.	2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP)	1999
Professor Herbie Newell Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson et al.	Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.	1999
Professor Herbie Newell	Clinical pharmacokinetics of antitumor antifolates	1999
Professor Herbie Newell	Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics	1999
Gordon Taylor Professor John Lunec Professor Andrew Pearson Professor Herbie Newell	Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines	1999
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson Emeritus Professor Bernard Golding et al.	In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors.	1999
Timothy Cressey Dr Michael Tilby Professor Herbie Newell	Mechanisms of drug specific loss of telomerase activity in testicular cancer cell lines	1999
Peter Smith Professor Alan Calvert Professor Herbie Newell Professor Nicola Curtin	MTA (LY231514) induced intracellular dNTP pool pertubations are alleviated by salvage of pre-formed purines and pyrimidines	1999
Peter Smith Hannah Barlow Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha(1)-acid glycoprotein.	1999
Dr Michael Tilby Professor Alan Calvert Professor Herbie Newell	Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels	1999
Dr Andrew Hughes Melanie Griffin Professor Alan Calvert Professor Herbie Newell Professor Alan Boddy et al.	Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days	1999
Michael Batey Kevin Fishwick Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert et al.	Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer	1999
Professor Nicola Curtin Professor Alan Calvert Professor barbara Durkacz Professor Herbie Newell	Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines.	1999
Professor Nicola Curtin Suzanne Kyle Lan Wang Professor barbara Durkacz Professor Roger Griffin et al.	Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors	1999
Professor Nicola Curtin Professor Alan Calvert Emeritus Professor Bernard Golding Professor Roger Griffin Professor Herbie Newell et al.	Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α1-acid glycoprotein binding	1999
Dr Christopher Calabrese Huw Thomas Michael Batey Professor Nicola Curtin Professor Roger Griffin et al.	Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase	1999
Peter Smith Professor Alan Calvert Professor Herbie Newell Professor Nicola Curtin	Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines	1999
Professor Gareth Veal Professor Alan Boddy Huw Thomas Annie Parry Professor Andrew Pearson et al.	Real-time monitoring of carboplatin pharmacokinetics in paediatric patients receiving high dose chemotherapy	1999
Dr John Lunn Professor Steve Wedge Professor Herbie Newell Professor Alan Calvert	O⁶-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma	1998
Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin Professor Herbie Newell et al.	2-phenylbenzimidazole-4-carboxamides are potent inhibitors of the DNA repair enzyme poly(ADP-ribose)-polymerase (PARP)	1998
Professor Andrew Pearson Professor Herbie Newell Mike Cole	A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children	1998
Timothy Cressey Dr Michael Tilby Professor Herbie Newell	Comparative effects of cisplatin and melphalan on telomerase activity in a testicular cell line	1998
Timothy Cressey Dr Michael Tilby Professor Herbie Newell	Comparative effects of DNA damaging drugs on telomerase activity in a testicular cell line	1998
Gordon Taylor Professor Herbie Newell Professor Alan Boddy Andrew Johnston Professor Andrew Pearson et al.	Deoxyuridine plasma levels during the phase I study of nolatrexed in children with advanced cancer	1998
Professor Herbie Newell Professor Alan Calvert Professor Anne Dickinson Professor Frederick Campbell Professor Nicola Curtin et al.	Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro	1998
Professor Alan Calvert Professor Herbie Newell Professor Nicola Curtin	Dipyridamole selectively potentiates antipurine antifolates in human tumour cell lines but not normal tissue targets of dose-limiting toxicity	1998
Noel Monks Professor Herbie Newell Professor Nicola Curtin	Induction of apoptosis in LoVo colorectal cells by the ADEPT system ZD2767: A comparison with chlorambucil and a mono-functional ZD2767 analogue	1998
Professor Jane Endicott Professor Martin Noble Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Insights into CDK inhibitor design from X-ray crystallographic studies	1998
Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al.	O-6-alkylguanines as selective inhibitors of cyclin dependent kinases	1998
Dr Andrew Hughes Melanie Griffin Professor Alan Calvert Andrew Johnston Professor Herbie Newell et al.	Pharmacokinetic interactions in a phase I study of nolatrexed (AG337, THYMITAQ ^TM) and paclitaxel in patients with advanced solid tumours	1998
Dr Anil Gholkar OBE Professor Herbie Newell Professor Andrew Pearson	Phase I study of temozolomide in paediatric patients with advanced cancer	1998
Peter Smith Professor Herbie Newell Professor Alan Calvert Professor Nicola Curtin	Potentiation of the in vitro activity of the multi-targeted antifolate MTA (LY231514) by dipyridamole	1998
Professor Alan Boddy Gordon Taylor Professor Herbie Newell Professor Alan Calvert	Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given prolonged administration in patients with solid tumors	1998
Professor Roger Griffin Professor Alan Calvert Professor Nicola Curtin Professor Herbie Newell Emeritus Professor Bernard Golding et al.	Resistance-modifying agents. 5.1 Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)	1998
Professor Herbie Newell	Selective cancer therapy with drugs - we've only just begun	1998
Dr Andrew Hall Professor John Lunec Professor Herbie Newell Professor Andrew Pearson Geoffrey Taylor et al.	Thymidylate synthase expression in nolatrexed and methotrexate-resistant human leukaemia cell lines	1998
Huw Thomas Professor Alan Boddy Professor Andrew Pearson Professor Herbie Newell	Validation of pharmacologically-guided dosing of carboplatin in paediatric patients	1998
Professor Alan Boddy Professor Andrew Pearson Dr Michael Tilby Professor Herbie Newell	Cisplatin pharmacokinetics in children with cancer	1997
Professor Herbie Newell	Inhibition of telomerase activity by cisplatin in human testicular cancer cells	1997
Professor Herbie Newell	Phase II study of 21 day schedule oral etoposide in children	1997
Dr Michael Tilby Professor Andrew Pearson Professor Alan Boddy Professor Herbie Newell	Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy	1997
Professor Alan Calvert Dr Andrew Hall Professor John Lunec Professor Herbie Newell Professor Andrew Pearson et al.	The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ® in human leukaemia and colorectal carcinoma cell lines	1997
Professor Steve Wedge Fiona Chapman Gordon Taylor Huw Thomas Professor Alan Boddy et al.	A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid	1996
Professor Alan Calvert Professor Herbie Newell	A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve	1996
Professor Herbie Newell Huw Thomas Professor Alan Calvert	Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters	1996
Professor Herbie Newell	Etoposide for the treatment of paediatric tumours: What is the best way to give it?	1996
Professor Alan Boddy Huw Thomas Professor Herbie Newell Professor Alan Calvert Lynsey Robson et al.	Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research campaign phase I/II committee study	1996
Dr Christine Arris Dr Christine Bleasdale Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Mechanism-based inhibition of O-6-methylguanine-DNA methyltransferase.	1996
Professor Roger Griffin Alex White Kenneth Bowman Professor Alan Calvert Professor Nicola Curtin et al.	Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme Poly(ADP-ribose)polymerase	1996
Professor Alan Boddy Professor Herbie Newell Professor Andrew Pearson	Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis	1996
Professor Herbie Newell Professor Andrew Pearson	Phase I trials in paediatric oncology - The European perspective - On behalf of the new agents group of the United Kingdom Childrens Cancer Study Group	1996
Professor Alan Boddy Professor Andrew Pearson Professor Herbie Newell	Population pharmacokinetics of carboplatin in children	1996
Dr Andrew Hall Professor Alan Calvert Dr James Sunter Professor Herbie Newell	The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients	1996
Professor Alan Boddy Mike Cole Professor Andrew Pearson Professor Herbie Newell	Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients	1995
Professor Alan Calvert Professor Alan Boddy Dr Andrew Hughes Lynsey Robson Huw Thomas et al.	Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.	1995
Gordon Taylor Professor Alan Boddy Professor Alan Calvert Andrew Johnston Professor Herbie Newell et al.	Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion	1995
Professor Steve Wedge Gordon Taylor Professor Alan Boddy Professor Alan Calvert Professor Herbie Newell et al.	Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement	1995
Professor Herbie Newell Professor Andrew Pearson	Exposure and schedule dependency of etoposide in neuroblastoma and leukaemia cells in vitro	1995
Professor Steve Wedge Gordon Taylor Professor Herbie Newell	Measurement of 5,10-dideaza-5,6,7,8-tetrahydrofolate (lometrexol) in human plasma and urine by high-performance liquid chromatography	1995
Professor Herbie Newell Professor Alan Calvert	Pharmacokinetics and Pharmacodynamics of Prolonged Oral Etoposide in Women with Metastatic Breast-Cancer	1995
Professor Herbie Newell Gordon Taylor Professor Alan Calvert	Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481)	1995
Professor Herbie Newell	Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe	1995
Professor Roger Griffin Professor Nicola Curtin Professor Herbie Newell Emeritus Professor Bernard Golding Professor barbara Durkacz et al.	The Role of Inhibitors of Poly(Adp-Ribose) Polymerase as Resistance-Modifying Agents in Cancer-Therapy	1995
Professor Herbie Newell	[Pt(CBDCA-O)(NH3)2(L-Methionine-S)]: Ring-opened adduct of the anticancer Drug Carboplatin ("Paraplatin"). Detection of a similar complex in drine by NMR spectroscopy	1994
Professor Herbie Newell	In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer	1994
Professor Herbie Newell	Editorial	1994
Professor Herbie Newell	Can pharmacokinetic and pharmacodynamic studies improve cancer chemotherapy?	1994
Professor Herbie Newell	Pharmacologically based phase I trials in cancer chemotherapy	1994
Dr Christine Arris Dr Christine Bleasdale Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Probing the active site and mechanism of action of O-6-methylguanine-DNA methyltransferase with substrate-analogs to (O-6-substituted guanines)	1994
Professor Alan Boddy Professor Andrew Pearson Dr Michael Tilby Professor Herbie Newell	The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in pediatric patients: A review.	1994
Dr Michael Tilby Professor Herbie Newell	Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy	1993
Professor Herbie Newell Professor Andrew Pearson Dr Michael Keir Professor Alan Calvert	Carboplatin Pharmacokinetics in Children - the Development of a Pediatric Dosing Formula	1993
Professor Andrew Pearson Professor Herbie Newell Mike Cole	Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation	1993
Professor Alan Calvert Angela Robinson Professor Herbie Newell	Long-Term Oral Etoposide in Metastatic Breast-Cancer - Clinical and Pharmacokinetic Results	1993
Professor Herbie Newell	Pharmacokinetic studies in mice with ICI D0490, a novel recombinant ricin A-chain immunotoxin	1993
Professor Herbie Newell Professor Steve Wedge	Pharmacokinetics of high molecular weight agents	1993
Professor Herbie Newell Professor Alan Calvert	Phase-I trial with pharmacokinetics of Cb10-277 given by 24 hours continuous infusion	1993
Professor Herbie Newell Professor Alan Calvert	Preclinical, Phase-I and Pharmacokinetic Studies with the Dimethyl Phenyltriazene-Cb10-277	1993
Professor Herbie Newell Professor Alan Calvert	Clinical Pharmacokinetics of the Anthrapyrazole Ci-941 - Factors Compromising the Implementation of a Pharmacokinetically Guided Dose Escalation Scheme	1992
Professor Alan Calvert Professor Herbie Newell	Future directions with carboplatin: Can Therapeutic Monitoring, High-Dose Administration, and Hematologic Support with Growth Factors Expand the Spectrum Compared with Cisplatin?	1992
Professor Herbie Newell Dr Ross Maxwell Emeritus Professor Bernard Golding	Invivo and exvivo magnetic resonance spectroscopy as applied to pharmacokinetic studies with anticancer agents: a review	1992
Professor Herbie Newell Professor Alan Calvert	Phase-I Trial of the Anthrapyrazole Ci-941 - Prospective Evaluation of a Pharmacokinetically Guided Dose-Escalation	1992
Professor Herbie Newell	¹H NMR studies of human urine: Urinary elimination of the anticancer drug carboplatin	1991
Professor Herbie Newell Geoffrey Taylor Professor Alan Calvert	The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N¹⁰-propargyl-5,8-dideazafolic acid (ICI 198583)	1991
Professor Herbie Newell Professor Alan Calvert	The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats	1991
Professor Herbie Newell Sarah Morgan Professor Alan Calvert	The renal effects of N-¹⁰-propargyl-5,8-dideazafolic acid (CB 3717) and a non-nephrotoxic analog ICI D 1694, in mice	1991
Dr John Lunn Professor Herbie Newell	Correlation between chemosensitivity to CB10-277 and O-6-alkyl-guanine-DNA alkyltransferase levels in human melanoma xenografts	1990
Professor Herbie Newell	Phase I clinical studies with cytotoxic drugs: Pharmacokinetic and pharmacodynamic considerations	1990
Professor Herbie Newell	The pharmacokinetics of oral lonidamine in breast and lung cancer patients	1990
Professor Herbie Newell Professor Alan Calvert	Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma	1989
Professor Alan Calvert Professor Herbie Newell	Carboplatin Dosage - Prospective Evaluation of a Simple Formula Based on Renal-Function	1989
Professor Herbie Newell Professor Alan Calvert	Determination of the Anthrapyrazole Anticancer Drug Ci-941 in Plasma and Urine by Solid-Phase Extraction and High-Performance Liquid-Chromatography	1989
Professor Nicola Curtin Professor Herbie Newell	Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole.	1989
Professor Herbie Newell	Pharmacokinetic determinants of the activity and toxicity of antitumor agents	1989
Professor Herbie Newell Professor Alan Calvert	Preclinical and Clinical Pharmacokinetic Studies with 1-(4-Carboxyphenyl)-3, 3-Dimethyl Triazene (CB10-277)	1989
Professor Herbie Newell Professor Alan Calvert	Quinazoline antifolates inhibiting thymidylate synthase: 2- desamino derivatives with enhanced solubility and potency	1989
Professor Herbie Newell Professor Alan Calvert	The pharmacokinetics and toxicity of the anthrapyrazole anti- cancer drug Ci-941 in the mouse - a guide for rational dose escalation in patients	1989
Professor Herbie Newell Gordon Taylor Professor Alan Calvert	Thymidylate synthase - a target for anticancer drug design	1989
Professor Herbie Newell Professor Alan Calvert	Development of an assay for the estimation of N¹⁰-propargyl- 5,8-dideazafolic acid polyglutamates in tumor cells	1988
Professor Herbie Newell Professor Alan Calvert	Formation and retention and biological activity of N¹⁰- propargyl-5,8-dideazafolic acid (CB 3717) polyglutamates in L1210 cells in vitro	1988
Professor Herbie Newell Professor Alan Calvert	Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin	1987
Professor Alan Calvert Professor Herbie Newell	Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717)	1987
Professor Herbie Newell Professor Alan Calvert	Tumor necrosis factor in man - clinical and biological observations	1987
Professor Alan Calvert Professor Herbie Newell	A Phase-I Evaluation of the Quinazoline Antifolate Thymidylate Synthase Inhibitor, N-10-Propargyl-5,8-Dideazafolic Acid, Cb3717	1986
Professor Herbie Newell Professor Alan Calvert	Pharmacokinetics of the thymidylate synthase inhibitor N¹⁰- propargyl-5,8-dideazafolic acid (CB 3717) in the mouse	1986
Professor Herbie Newell Professor Alan Calvert	The effect of the nucleoside transport inhibitor dipyridamole on the incorporation of H³ thymidine in the rat	1986
Professor Alan Calvert Professor Herbie Newell	Phase-I Studies with Carboplatin at the Royal-Marsden-Hospital	1985
Professor Alan Calvert Professor Herbie Newell	Quinazoline antifolates inhibiting thymidylate synthase: variation of the N-¹⁰ substituent	1985
Professor Herbie Newell Professor Alan Calvert	The clinical pharmacokinetics of the novel antifolate N¹⁰- propargyl-5,8-dideazafolic acid (CB 3717)	1985
Professor Herbie Newell Professor Alan Calvert	Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function	1984
Professor Herbie Newell Professor Alan Calvert	Studies on the pharmacokinetics of chlorambucil and prednimustine in man	1983
Professor Alan Calvert Professor Herbie Newell	Early Clinical-Studies with Cis-Diammine-1,1-Cyclobutane Dicarboxylate Platinum-Ii	1982